Filing Flows › Elite Pharmaceuticals (ELTP) › Gross margin
Elite Pharmaceuticals (ELTP) gross margin by quarter
Elite Pharmaceuticals' gross margin was 41.7% in Q1 FY27 (first quarter fiscal 2027), -9.2 pts from Q4 FY26. Over the last 5 quarters it ranged from 38.7% (Q2 FY26) to 54.1% (Q4 FY25).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q1 FY27 | 41.7% | -9.2 pts | — |
| Q4 FY26 | 51.0% | +10.0 pts | -3.1 pts |
| Q3 FY26 | 41.0% | +2.3 pts | — |
| Q2 FY26 | 38.7% | -15.3 pts | — |
| Q4 FY25 | 54.1% | — | — |
Q1 FY27 at a glance
Elite Pharmaceuticals, Q1 FY27: revenue $32.4M (-20% year over year), operating margin 23.3%, net earnings $5.9M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Elite Pharmaceuticals' gross margin?
Elite Pharmaceuticals' gross margin was 41.7% in Q1 FY27 (first quarter fiscal 2027), -9.2 pts from Q4 FY26.
How has Elite Pharmaceuticals' gross margin changed?
Over the last 5 quarters it ranged from 38.7% (Q2 FY26) to 54.1% (Q4 FY25).